Kornimate/medical-research-clean huggingface dataset:
evaluating the episodic future thinking intervention for reducing cigarette consumption in cigarette smokers

Conditions: Cigarette Smoking-Related Carcinoma

Summary: this clinical trial evaluates the effectiveness of active episodic future thinking (eft) stimuli for reducing cigarette consumption in cigarette smokers. eft is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. active eft stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. control eft stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. active eft stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.

primary objeective: i. to evaluate the efficacy of episodic future thinking (eft) for smoking cessation. outline: participants are randomized to 1 of 2 arms. arm i (active): participants receive the active eft stimulus and use the icoquit smokerlyzer carbon monoxide monitor on study. arm ii (control): participants receive the control eft stimulus and use the icoquit smokerlyzer carbon monoxide monitor on study.

Eligibility criteria:
inclusion criteria: * smoke \>= 10 cigarettes daily * \>32 on the vividness of visual imagery questionnaire (vviq) * no regular use of other tobacco products * in possession of a smartphone with text messaging capabilities * willing to quit smoking in the next 30 days * low socioeconomic status * veteran of the us armed services exclusion criteria: * unable or unwilling to provide verbal consent * unable or unwilling to provide data to the research team * current use of nicotine replacement therapy, bupropion, or varenicline * use of drugs of abuse in the past 30 days * living in the same household as a participant already enrolled in this study * unable or unwilling to use nicotine patches
sulfonylurea effects on glucagon regulation during hypoglycemia in type 1 dm

Conditions: Diabetes Mellitus, Type 1

Summary: we aim to demonstrate that oral administration of glibenclamide stimulates pancreatic glucagon secretion during hypoglycemia in insulin-deficient (c-peptide negative) patients with type 1 diabetes when compared to type 1 diabetic patients with residual insulin secretion (c-peptide positive).

the glucagon response during insulin induced hypoglycemia and rate of glucose recovery will be monitored in 10 c-peptide positive and 10 c-peptide negative patients with type 1 dm following the application of glibenclamide and placebo in a randomized, single-blind, cross-over study. cognitive function during hypoglycemia with and without glibenclamide pretreatment will be a secondary outcome.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 50 years * patients diagnosed with c-peptide negative diabetes type 1 (c-peptide \<200 pmol/l 6 min after 1 mg glucagon i.v. at plasma glucose concentrations between 5 and 11 mmol/l) * patients diagnosed with c-peptide positive diabetes type 1 (c-peptide \> 500 pmol/l 6 min after 1 mg glucagon i.v. at plasma glucose concentrations between 5 and 11 mmol/l) * stable metabolic control; hba1c levels \<8.0 % and without episodes of antecedent severe hypoglycemias in the past four weeks exclusion criteria: * patients treated with medications potentially interfering with glucose metabolism, such as systemic steroids, immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus), highly active antiretroviral therapy * history coronary artery disease * history of epilepsy or seizures * current smokers * any significant or unstable hepatic, cardiac, pulmonary, renal, neurological, musculoskeletal, hematological or endocrine disease. * pregnant or breast feeding women * woman of childbearing potential not using a reliable method of birth control such as oral contraceptives or iud. * subjects refusing or unable to give written informed consent

Keywords: diabetes mellitus type 1 hypoglycemia sulfonylurea glucagon
the effects of ultrasound guided genicular nerve block for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: goal: comparison of the effects of genicular nerve block with usg and physical therapy on pain, physical function for patients with knee osteoarthritis. material and methods:102 patients with osteoarthritis of the knee with kellgren-lawrence (k-l) class 2 or 3 were included in the study.patients were randomized to two groups, first being injected a total of 6 ml of lidocaine plus 40 mg of triamcinolone (ta) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves with exercise treatment and second being ten sessions of hotpack as a surface warmer, tens as a analgezic current, ultrasound therapy as a deep warmer with exercise treatment.for the first group, the ultrasound we used: 12 mhz linear transducer. (logic e9-ge, usa).the transducer was first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. the genicular arteries were identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color doppler ultrasound.accordingly, gnb target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve. , visual analogue scale for pain(vas) was primer outcome measurement, western ontorio and mcmaster universities osteoarthritis index (womac) and six minute walk tests were seconder outcome measurements of the study applied before, after (two weeks) and 12th weeks of treatment. primer endpoint of the study is decrease at least 40% in vas values at 2nd week, second endpoint is the improvement in the womac and 6-minute walk test observed in the 2nd week continues until the 12th week.


Eligibility criteria:
inclusion criteria: * diagnosed with knee osteoarthritis according to the 1986 american college of rheumatology (acr) criteria and were in kellgren-lawrence (kl) grade 2-3 * being between the ages of 45-65 exclusion criteria: * severe knee trauma history within the six month * previous intraarticular hyaluronic acid or steroid injection * previous use of oral glucosamine * meniscal or connective tissue damage * those receiving physical therapy within the six month for knee pain * history of inflamatuary romatologic disease * pregnancy and breastfeeding * malignancy * psychiatric disease * those with a pacemaker
neural mechanisms and predictors of an ultra-brief suicide prevention strategy

Conditions: Suicide

Summary: the current study is a clinical trial, meaning a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related behavioral outcomes. specifically, male and female adults with current suicidal intent will be randomly assigned to receive either a 1-hour session of crisis response planning (crp) or a 1-hour session of standard crisis risk management (treatment as usual). the effects of both conditions on changes in emotion regulation, behavioral inhibition, stress reactivity, and suicide risk will be evaluated post-intervention and at six-month follow-up. additional assessments of changes in mood and suicidality will be collected daily during the first 10-days following intervention, and then monthly for a duration of six months. a cohort of healthy controls is included in the study but are not randomized to either treatment condition. the investigators hypothesize the following: 1) a single session of crp will acutely change suicide risk and 2) individuals who receive crp will show sustained improvements in measures of suicidality when compared to individuals who received the treatment as usual intervention.


Eligibility criteria:
inclusion criteria: * generally medically and neurologically healthy * age 18 years or older at the time of consent * willing and able to give informed consent * individuals in the acutely suicidal group: endorse current suicide intent as indicated by a total score of 5 or greater on the beck's scale for suicidal ideation. exclusion criteria: * medical or neurologic condition or neurocognitive dysfunction that would interfere with the study * current or past manic/hypomanic episode, schizophrenia, or psychotic symptoms * deafness in either ear * currently pregnant or trying to become pregnant * electroconvulsive therapy (ect) within the past 6 months * current moderate to severe substance use disorder * lack of fluency in english * positive alcohol breathalyzer test and/or acute drug intoxication the day of the fmri scans * unwilling or unable to sign the informed consent document * under 18 years old at the time of enrollment * traumatic brain injury from a suicide attempt or another event * presence of ferrous-containing metals within the body * inability to tolerate small, enclosed spaces without significant anxiety * individuals enrolled as controls: no lifetime history of any dsm-5 disorder * individuals enrolled as controls: no lifetime history of suicide ideation or intent

Keywords: suicide prevention crisis response planning suicide functional magnetic resonance imaging
guideline vs usual treatment in schizophrenic adolescents

Conditions: Schizophrenia

Summary: the purpose of this study was to evaluate the applicability and usefulness of the guideline treatment for diagnosis and treatment of adolescents with schizophrenia, also to evaluate the compliance to the treatment according to the guidelines, and to compare the treatment compliance, severity of illness and social functioning of patients treated according to guideline treatment vs patients with the treatment as usual on a six month follow up.

the drug treatment of patients on the guideline treatment group followed an algorithm, where an atypical antipsychotic must be maintained during 6 weeks before the evaluation of medication change if the panss score did not show a reduction of 30% and the patients did not show functional improvement. clozapine could be administered if two trials of antipsychotics were not effective. benzodiazepines, antidepressants, anticholinergics or anticonvulsants were allowed for the treatment of comorbid disorders or side effects. the psychosocial treatment included psychoeducation (three 90 min sessions with the family and two 45 min sessions with the patients), followed by a seven 45 min sessions training on social skills which focused on verbal and non-verbal communication, as well as in conversation skills. patients were also trained in healthy life style habits and were included on a 30 min of exercise in group. tau included an antipsychotic and the psychosocial treatment decided by the clinician

Eligibility criteria:
inclusion criteria: * total score ≥ 70 on the positive and negative syndrome scale (panss) and a score of at least 4 (moderate) on 3 of the follow core items (conceptual disorganization , hallucinatory behavior, suspiciousness, and unusual thought content). * patients were required to have a score of ≥ 4 symptoms on the clinical global impression improvement scale (cgi-s) * had not received antipsychotic in proper doses/ a regular antipsychotic treatment for at least 4 weeks previous enrollment. exclusion criteria: * unstable medical conditions * their diagnosis changed during the study * had a history of substance dependence or substance use (except cannabis), -females with pregnancy * refusal to practice contraception during the study.

Keywords: schizophrenia adolescents treatment guidelines
identification of a plasma proteomic signature for lung cancer

Conditions: Precancerous Conditions; Carcinoma

Summary: the primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this irb/ec approved study with pulmonary nodules.

blood samples are obtained from those patients undergoing procedures to determine if a lung nodule is benign or cancerous. the data from the study will not be used to guide or influence the treatment of the patients enrolled in this study. there is no change from the normal standard of care that patients receive.

Eligibility criteria:
inclusion criteria: * age ≥ 40 * any smoking status, e.g. current, former, or never * co-morbid conditions, e.g. copd * nodule size ≥ 4 mm and ≤ 30 mm (up to stage 2b eligible), any spiculation or ground glass opacity * pathology: malignant - adenocarcinoma, squamous, or large cell * pathology: benign - inflammatory (e.g. granulomatous, infectious) or non-inflammatory (e.g. hamartoma) * clinical stage, primary tumor: ≤t2 (e.g. 1a, 1b, 2a and 2b) * clinical stage, regional lymph nodes: n0 or n1 only * clinical stage, distant metastasis: m0 only exclusion criteria: * prior malignancy within 5 years of lung nodule diagnosis * no nodule size available * no pathology data available for those with * current diagnosis of non-small cell lung cancer * clinical stage: primary tumor ≥t3; regional lymph nodes: ≥n2; 4 distant metastasis: ≥m1

Keywords: precancerous conditions carcinoma
iop lowering efficacy of travoprost/brinzolamide fixed combination ophthalmic suspension in patients with open-angle glaucoma or ocular hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to compare the safety and iop-lowering efficacy of a fixed combination of travoprost/brinzolamide ophthalmuc suspension dosed bid and qd, to travatan dosed qd and a vehicle dosed bid in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older of either sex and any race with diagnosed open-angle glaucoma or confirmed ocular hypertension exclusion criteria: * age (under 18)

Keywords: open-angle glaucoma ocular hypertension
norepinephrine consumption after prophylactic ondansetron

Conditions: Maternal Hypotension

Summary: this study evaluates the effect of prophylactic ondansetron on the incidence of spinal hypotension and vasopressor consumption in caesarean section patients using norepinephrine treatment. half of participants receive ondansetron before spinal anesthesia while the other half receive saline.

spinal hypotension in cesarean section patients can occur vigorously and may lead to cardiovascular collapse. if doesn't treated precipitously, it can cause maternal hypotension, nausea and vomiting and fetal acidosis. recently norepinephrine has been proposed for the prevention and treatment of spinal hypotension with less tendency to decrease hr and co. it has been reported that ondansetron can be used for prophylaxis and treatment of nausea and vomiting, may also reduce the vasopressor requirement in patients undergoing caesarean section with spinal anesthesia. the aim of the present study is to assess the effect of prophylactic ondansetron on norepinephrine consumption and incidence of spinal hypotension, and side effects such as maternal nausea, vomiting and bradycardia.

Eligibility criteria:
inclusion criteria: * asa physical status i-ii patients * between the ages of 18 and 40 years * scheduled for elective caesarean section with spinal anesthesia exclusion criteria: * history of hypertension * history of severe hepato-renal disease, * sensitivity or contraindication to ondansetron, * drug or alcohol abuse * contraindication to regional anesthesia.
dance workshop for institutionalized seniors with behavioral and psychological symptoms of dementia

Conditions: Dementia

Summary: it is estimated that the prevalence of dementia in france is 5% for people over 65 years of age and that this increases to 18% for people over 75 years of age. behavioral disorders are frequent in patients with dementia and are the main cause of institutionalization, representing up to 50% of cases. dementia syndromes can be translated into behavioral and psychological symptoms of dementia (bpsd), which are defined as perceptual, mood or behavioral disorders. to date, there is no cure for dementia, but certain measures can be taken to reduce symptoms. the has suggests that physical exercise would reduce bpsd and could improve the ability to perform activities of daily living or slow down the cognitive decline of this type of patient. indeed, several articles have highlighted the benefits of physical activity in demented patients. a meta-analysis has shown a significant decrease in bpsd via the neuropsychiatric inventory (npi) score. nevertheless, it is often observed that there is a difficulty in adhering to the program in very elderly population groups. dance is a complete physical activity that integrates physical, cognitive and social elements. a meta-analysis has shown that dance has a significant effect on global cognition but also on neuroplasticity and physical functioning in patients with mental disorders. the music component of dance also has an effect on the behavioral problems of demented patients, stimulating language ability and social and emotional function. however, at present, no study of good methodological quality has been able to demonstrate the effectiveness of dance-based physical activity for the treatment of dementia symptoms. as a result of these findings, the apaise project was developed and should help slow the onset of bpsd in patients with dementia.


Eligibility criteria:
inclusion criteria: 1. institutionalized patient (male or female) over 65 years of age ; 2. patient with behavioral problems, as measured by an npi-es \> 3 on any item and an npi-es impact scale \> 2 ; 3. patient able to mobilize the upper body at a minimum (arms, trunk, head); 4. medication (antipsychotics, antidepressants, anxiolytics and related hypnotics) without major modification for at least 30 days prior to inclusion after medical advice; 5. possibility of including patients under guardianship or curatorship; 6. patient affiliated to a social security plan; 7. obtaining consent from the patient or legal representative. exclusion criteria: 8. inability of the patient to follow the sessions (e.g., major visual/auditory disabilities), difficult follow-up, or any other reason at the discretion of the investigator; 9. inability of the health care team to complete the npi-es questionnaire for the patient; 10. patient has a concurrent psychiatric disorder (e.g., bipolar disorder, schizophrenia, or other).
hyperbaric oxygen therapy for peripheral neuropathy due to paclitaxel analogs

Conditions: Breast Cancers

Summary: the goal of this study was to explore the safety and efficacy of hyperbaric oxygen in the treatment of peripheral neuropathy due to paclitaxel analogues


Eligibility criteria:
inclusion criteria: 1. patients with newly diagnosed breast cancer by pathology 2. age 18-60 years 3. ecog 0-2 4. cipn patients with nci-ctcae grade 1 or higher after treatment with paclitaxel-based drugs exclusion criteria: 1. patients with contraindications to hyperbaric oxygen i. untreated pneumothorax. ii. concomitant administration of disulfiram. iii. concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. iv. premature and/or low body mass newborns. iv. premature and/or low body mass neonates. 2. other cancers
dapagliflozin post marketing surveillance in hf and ckd

Conditions: Heart Failure; Chronic Kidney Disease

Summary: this is an observational, non-interventional, single-arm multicenter study. the objectives of this study are to assess safety and effectiveness of forxiga in a real world setting in patients who are prescribed with the study drug according to the newly approved indications in the republic of korea

as part of a post-approval commitment, the ministry of food and drug safety (mfds) of the republic of korea (hereinafter "korea") requests a study to characterize the safety in patients treated with dapagliflozin by physicians in normal clinical practice settings. in principle, all patients treated with the product in accordance with the newly updated local prescribing information for hf and/or ckd are eligible for the enrolment in this study. product prescription and patient enrollment will depend on physicians' medical decision as per routine clinical practice. patient follow-up will be 12 weeks or about 24 weeks (for long-term surveillance) and patients will be recruited over a period of 4 years after the new hfref indication approval by the local health authorities. this is due to the requirements from the local health authorities. the primary objective of this study is to assess the safety profile of the product in korean adult patients with heart failure (hf) and/or chronic kidney disease (ckd) in a real world setting under the approved indication(s) in korea. the secondary objective of this study is to examine the effectiveness of the product in korean patients with 1) hf and/or 2) ckd in a real world setting under the approved indication(s) in korea. the exploratory objective of this study is to identify patients' baseline characteristics that might be associated with the safety and effectiveness of the product when prescribed under the newly approved indication(s) in korean patients with 1) hf and/or 2) ckd during the 12 weeks or about 24 weeks of follow-up duration.

Eligibility criteria:
inclusion criteria: * patients aged 19 years old and older * patients eligible for the product treatment (i.e. on-label treatment) according to the newly approved hf and/or ckd label in korea * provision of signed and dated written informed consent by the patient or legally acceptable representative exclusion criteria: * participation in any interventional trial during the treatment with the product. * any off-label indications that are not in accordance with the newly approved label in korea. * any contraindications for the use of the product (as described in the local prescribing information). * prior use of product, as per local mfds guidance.
evaluation of the impact of a sugar-sweetened beverage tax in chile

Conditions: Chronic Disease; Obesity

Summary: the purpose of this study is to evaluate formally the short term impacts of the tax policy applied to sugar-sweetened beverages (ssbs) in chile. the impuesto adicional a las bebidas analcohólicas (iaba, or "additional tax on soft drinks") in chile was enacted in october 2014, affecting any non-alcoholic beverages to which colorants, flavourings or sweeteners have been added. for beverages above an added sugar concentration of at least 6.25 grams per 100ml (or equivalent proportion), the tax was increased from 13% to 18%, while for those below this threshold the tax was decreased to 10%, producing an 8% tax difference between these beverage groups. this impact evaluation analysis of the chilean sugar-sweetened beverage (ssb) tax will estimate the impact of increasing the tax as well as decreasing the tax on soft drinks. the study will use household level grocery purchasing data for chile. the purchasing records are available from october 2011 to september 2015 (three years before; and one year after the implementation of the tax in october 2014). the investigators will use a series of quasi-experimental approaches to evaluate the causal impact of the ssb tax policy on consumers' behaviour as well as on industry responses in the form of pricing and price promotion decisions.


Eligibility criteria:
inclusion criteria: * household in chile that agreed to participate in the purchasing survey and provided data to a satisfactory degree for the first 2 months. exclusion criteria: * households that are unwilling to participate in the survey. households that change physical address. households with poor compliance to the survey.

Keywords: taxes beverages/economics carbonated beverages/economics diet, food and nutrition/economics economics energy intake risk factors